Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142883 | 0.87 | ITGA4 (0.55) | MAPK1ITGA4ITGB1ITGB7 | |
| SCHEMBL3823375 | 0.85 | ITGA4 (0.45) | ITGA4ITGB1ITGB7 | |
| SCHEMBL3835309 | 0.84 | L3MBTL1 (0.53) | MAPK1ITGA4ITGB1ITGB7NPSR1 | |
| SCHEMBL3834520 | 0.83 | ITGB1 (0.55) | ITGA4ITGB1ITGB7 | |
| SCHEMBL13851485 | 0.83 | ITGA4 (0.53) | ITGA4ITGB1ITGB7 | |
| SCHEMBL3818080 | 0.81 | MMP2 (0.42) | ITGA4ITGB1ITGB7 | |
| SCHEMBL4159347 | 0.80 | ITGA4 (0.52) | ITGA4ITGB1ITGB7 | |
| SCHEMBL3831956 | 0.80 | ITGA4 (0.50) | ITGA4ITGB1ITGB7 | |
| SCHEMBL3837273 | 0.80 | ITGA4 (0.54) | ITGA4ITGB1ITGB7 | |
| SCHEMBL3835951 | 0.80 | ITGA4 (0.52) | ITGA4ITGB1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | claimed |
| EP-2091916-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | AstraZeneca AB (SE) | 2009-08-26 | — | — | EP | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | MAPK1 2101/4885ITGA4 23/4885ITGB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.